Home
About
Overview
Sharing Data
ORCID
Help
History (6)
Deucravacitinib in patients with inflammatory bowel disease: 12-week efficacy and safety results from 3 randomized phase 2 studies in Crohn's disease and ulcerative colitis.
Efficacy and safety of filgotinib as induction and maintenance therapy for Crohn's disease (DIVERSITY): a phase 3, double-blind, randomised, placebo-controlled trial.
Risankizumab efficacy and safety based on prior inadequate response or intolerance to advanced therapy: post hoc analysis of the INSPIRE and COMMAND phase 3 studies.
The Effect of Etrasimod on Fecal Calprotectin and High-sensitivity C-reactive Protein: Results From the ELEVATE UC Clinical Program.
Successful Treatment of Severe Pyoderma Gangrenosum and Ulcerative Colitis With Upadacitinib.
See All 6 Pages
Find People
Find Everything
Login
to edit your profile (add a photo, awards, links to other websites, etc.)
Edit My Profile
My Person List (
0
)
Return to Top
Successful Treatment of Severe Pyoderma Gangrenosum and Ulcerative Colitis With Upadacitinib.
Successful Treatment of Severe Pyoderma Gangrenosum and Ulcerative Colitis With Upadacitinib. ACG Case Rep J. 2024 Oct; 11(10):e01531.
View in:
PubMed
authors with profiles
David Rubin